A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes

<b>Objective</b>: This study aimed to investigate the prognostic value of the preoperative monocyte-to-high-density lipoprotein cholesterol ratio (MHR) and clinicopathological parameters for predicting survival outcomes in patients undergoing curative-intent gastrectomy for gastric adenocarcinoma. <b>Methods</b>: This retrospective cohort study analyzed data from 304 patients with histopathologically confirmed gastric adenocarcinoma who underwent curative-intent gastrectomy with standardized D1+ or D2 lymphadenectomy. The MHR was calculated using preoperative monocyte counts and HDL cholesterol levels. Patients were dichotomized based on the optimal MHR cutoff determined via receiver operating characteristic curve analysis with the Youden index. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using Kaplan-Meier analysis and compared with log-rank tests. <b>Results</b>: ROC analysis determined an optimal MHR cutoff of ≥11.02 (AUC: 0.654; 95% CI: 0.59-0.718), yielding sensitivities and specificities of 62.6% and 62.4%, respectively. Patients with an elevated MHR (≥11.02) had worse 5-year OS (51.4 vs. 72.2%; <i>p</i> < 0.001) and PFS (65.2 vs. 80.5%; <i>p</i> = 0.003). In the multivariate Cox regression model, elevated MHR emerged as an independent predictor of disease progression (HR: 1.93; 95% CI: 1.17-3.18; <i>p</i> = 0.010), while parameters such as signet ring cell histology, lymphovascular invasion, and perineural invasion were significant in univariate analyses but not in the adjusted multivariate model. <b>Conclusions</b>: MHR should not be regarded as a definitive predictor in isolation but rather as a cost-effective, readily obtainable adjunct within a broader preoperative risk assessment framework. Integration with other inflammation-based and clinicopathological factors may enhance predictive performance and clinical applicability.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-08-28
DOI
https://doi.org/10.3390/cancers17172816
Citations
1
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes

Mehmet Salim Demir, Gözde Ağdaş
1 citations
Cancers
Gastric Cancer Management and Outcomes
1.52
article

A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes

Mehmet Salim Demir, Gözde Ağdaş
article en
1 citations

Abstract

<b>Objective</b>: This study aimed to investigate the prognostic value of the preoperative monocyte-to-high-density lipoprotein cholesterol ratio (MHR) and clinicopathological parameters for predicting survival outcomes in patients undergoing curative-intent gastrectomy for gastric adenocarcinoma. <b>Methods</b>: This retrospective cohort study analyzed data from 304 patients with histopathologically confirmed gastric adenocarcinoma who underwent curative-intent gastrectomy with standardized D1+ or D2 lymphadenectomy. The MHR was calculated using preoperative monocyte counts and HDL cholesterol levels. Patients were dichotomized based on the optimal MHR cutoff determined via receiver operating characteristic curve analysis with the Youden index. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using Kaplan-Meier analysis and compared with log-rank tests. <b>Results</b>: ROC analysis determined an optimal MHR cutoff of ≥11.02 (AUC: 0.654; 95% CI: 0.59-0.718), yielding sensitivities and specificities of 62.6% and 62.4%, respectively. Patients with an elevated MHR (≥11.02) had worse 5-year OS (51.4 vs. 72.2%; <i>p</i> < 0.001) and PFS (65.2 vs. 80.5%; <i>p</i> = 0.003). In the multivariate Cox regression model, elevated MHR emerged as an independent predictor of disease progression (HR: 1.93; 95% CI: 1.17-3.18; <i>p</i> = 0.010), while parameters such as signet ring cell histology, lymphovascular invasion, and perineural invasion were significant in univariate analyses but not in the adjusted multivariate model. <b>Conclusions</b>: MHR should not be regarded as a definitive predictor in isolation but rather as a cost-effective, readily obtainable adjunct within a broader preoperative risk assessment framework. Integration with other inflammation-based and clinicopathological factors may enhance predictive performance and clinical applicability.

CancersVol. 17(17)
Education Training And Research (US)
Openalex Percentile: Top 15%
Gastric Cancer Management and Outcomes
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Novel Non-Invasive Biomarker for Gastric Cancer: Monocyte-to-HDL Ratio and Clinicopathological Parameters in Predicting Survival Outcomes — Mehmet Salim Demir, Gözde Ağdaş · Cancers (2025) | TGRS Research Map | TGRS